

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A09/2017 WB

DESPATCHED ON 03RD OCTOBER 2017

HLA PHENOTYPE OF BLOOD DONOR: A1, A2; B44, B60; Cw5, Cw10; DR4, DR9; DQ7, DQ8

				Summary of Results												
				PBL				T-Cells				B-Cells				
				5	8	8	8	16	16	16	16	14	13	14	13	
				0	0	0	1	0	0	0	0	5	3	0	2	
				5	8	8	7	16	16	16	16	9	10	14	11	
				5	2	2	2	4	4	4	4	7	8	7	8	
				0.0%	0.0%	0.0%	12.5%	0.0%	0.0%	0.0%	0.0%	35.7%	23.1%	0.0%	15.4%	
				100.0%	100.0%	100.0%	87.5%	100.0%	100.0%	100.0%	100.0%	64.3%	76.9%	100.0%	84.6%	
Consensus				Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Not Assessed	Negative	Negative	Negative	
HLA Antibody Specificity (Defined By CDC)				DR5 DR6 DQ6	DQ3	B7 DR2	Multi	DR5 DR6 DQ6	DQ3	B7 DR2	Multi	DR5 DR6 DQ6	DQ3	B7 DR2	Multi	
				Without DTT				Without DTT				Without DTT				
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments
9	YES	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	Poor cell viability
11	YES	YES	YES	Equivocal	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT	B-cell results not reported due to poor viability
12	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
20	YES		YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT	B cell testing not possible due to dynabead product recall and on going validation of new B cell separation technique
23		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	Samples were two days old on receipt. Condition of cells precluded confident analysis. A technical problem relating to Dynabead separation was also encountered and is under review
24		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
25		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
28		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	Poor viability for both T and B-cells
34		YES	YES					Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	
35	YES	YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative					
38	YES	YES	YES	NT	NT	NT	NT	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	PBL results were not valid because the cell viability was too low.
39		YES	YES					Negative	Negative	Negative	Negative	Positive	Positive	Negative	Positive	
41		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	Samples went missing after delivery
42	YES		YES	Negative	Negative	Negative	Negative					Negative	Negative	Negative	Negative	
45		YES	YES					Negative	Negative	Negative	Negative	Positive	Equivocal	Negative	Equivocal	
51		YES	YES					Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	The quality of the cells was very poor.
54		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
58		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
117	YES			Equivocal	Negative	Negative	Negative									
136		YES						Negative	Negative	Negative	Negative					
149	YES			Equivocal	Negative	Negative	Negative									
205	YES		YES	Negative	Negative	Negative	Positive					Negative	Negative	Negative	Positive	
212		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
311		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
315		YES	YES					Equivocal	Equivocal	Equivocal	Equivocal	Equivocal	Equivocal	Equivocal	Equivocal	There is a very bad viability, all is positive because of dead cells, and we can't give a result

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A09/2017 WB

DESPATCHED ON 03RD OCTOBER 2017

Lab No.	PBL without DTT				T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	10	25	10
11	Equivocal	-	-	-	-	-	-	-	NT	NT	NT	NT	85	95	50
12	1	1	1	1	1	1	1	1	1	1	1	1	90	90	80
20	1	1	1	1					NT	NT	NT	NT	80		
23					NT	NT	NT	NT	NT	NT	NT	NT		30	40
24					20	10	10	10	80	40	30	40		90	70
25					1	1	1	1	1	1	1	1		99	95
28					1	1	1	2	NT	NT	NT	NT		85	80
34					1	1	1	1	4	4	1	1		95	88
35	1	1	1	1	1	1	1	1					80	40	
38	NT	NT	NT	NT	1	1	1	1	1	1	1	1	60	99	90
39					-	-	-	-	2	2	-	4		95	95
41					NT	NT	NT	NT	NT	NT	NT	NT			
42	<10	<10	<10	<10					<10	<10	<10	<10	90		85
45					1	1	1	1	4	2	1	2		95	80
51					0	0	0	0	4	4	0	0		95	95
54					<10	<10	<10	<10	11-20	21-30	21-30	21-30		>90	>80
58					5	5	5	5	10	10	10	10		95	85
117	1	1	1	1									72		
136					1	1	1	1						98	
149	Equivocal	-	-	-									72		
205	-	-	-	++					-	-	-	++	80		80
212					-	-	-	-	-	-	-	-		100	100
311					1	1	1	1	1	1	1	1		100	90
315					Equivocal	Equivocal	Equivocal	Equivocal	Equivocal	Equivocal	Equivocal	Equivocal		50	25

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A09/2017 WB

DESPATCHED ON 03RD OCTOBER 2017

HLA PHENOTYPE OF BLOOD DONOR: A1, A2; B44, B60; Cw5, Cw10; DR4, DR9; DQ7, DQ8

				Summary of Results												
				PBL				T-Cells				B-Cells				
				5	7	7	7	15	15	15	15	14	14	14	14	
Total tested				0	0	0	1	0	0	0	0	2	2	0	1	
Positive				5	7	7	6	15	15	15	15	12	12	14	13	
Negative				4	2	2	2	3	3	3	3	6	6	6	6	
NT/Equivocal				0.0%	0.0%	0.0%	14.3%	0.0%	0.0%	0.0%	0.0%	14.3%	14.3%	0.0%	7.1%	
% Positive				100.0%	100.0%	100.0%	85.7%	100.0%	100.0%	100.0%	100.0%	85.7%	85.7%	100.0%	92.9%	
% Negative																
<b>Consensus</b>				<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	
HLA Antibody Specificity (Defined By CDC)				DR5 DR6 DQ6	DQ3	B7 DR2	Multi	DR5 DR6 DQ6	DQ3	B7 DR2	Multi	DR5 DR6 DQ6	DQ3	B7 DR2	Multi	
Lab No.	PBL Assessment	T Cell Assessment	B Cell Assessment	With DTT				With DTT				With DTT				Comments
				Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
9	YES	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	Poor cell viability
11	YES	YES	YES	Equivocal	Negative	Negative	Negative	Negative	Negative	Negative	Negative	NT	NT	NT	NT	
12	YES	YES	YES	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
15		YES	YES									Negative	Negative	Negative	Negative	
20	YES		YES	Negative	Negative	Negative	Negative					NT	NT	NT	NT	B cell testing not possible due to dynabead product recall and on going validation of new B cell separation technique
24		YES	YES					Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
25		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
28		YES	YES					Negative	Negative	Negative	Negative	NT	NT	NT	NT	Poor viability for both T and B-cells
34		YES	YES					Negative	Negative	Negative	Negative	Negative	Positive	Negative	Negative	
35	YES	YES		Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative					
38	YES	YES	YES	NT	NT	NT	NT	Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	PBL results were not valid because the cell viability was too low.
39		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
41		YES	YES					NT	NT	NT	NT	NT	NT	NT	NT	Samples went missing after delivery
42	YES		YES	Negative	Negative	Negative	Negative					Negative	Negative	Negative	Negative	
45		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
51		YES	YES					Negative	Negative	Negative	Negative	Positive	Positive	Negative	Negative	The quality of the cells was very poor.
58		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
149	YES			Equivocal	Negative	Negative	Negative									
205	YES		YES	Negative	Negative	Negative	Positive					Negative	Negative	Negative	Positive	
212		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
311		YES	YES					Negative	Negative	Negative	Negative	Negative	Negative	Negative	Negative	
315		YES	YES					Equivocal	Equivocal	Equivocal	Equivocal	Equivocal	Equivocal	Equivocal	Equivocal	There is a very bad viability, all is positive because of dead cells, and we can't give a result

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A09/2017 WB

DESPATCHED ON 03RD OCTOBER 2017

Lab No.	PBL with DTT				T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
9	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	10	25	10
11	Equivocal	-	-	-	-	-	-	-	NT	NT	NT	NT	85	95	50
12	1	1	1	1	1	1	1	1	1	1	1	1	90	90	80
15					0	0	0	0	0	0	0	0		95	95
20	1	1	1	1					NT	NT	NT	NT	80		
24					20	10	10	10	70	40	30	30		90	70
25					1	1	1	1	1	1	1	1		99	95
28					1	1	1	1	NT	NT	NT	NT		85	80
34					1	1	1	1	1	2	1	1		95	88
35	1	1	1	1	1	1	1	1					80	40	
38	NT	NT	NT	NT	1	1	1	1	1	1	1	1	60	99	90
39					-	-	-	-	-	-	-	-		95	95
41					NT	NT	NT	NT	NT	NT	NT	NT			
42	<10	<10	<10	<10					<10	<10	<10	<10	90		85
45					1	1	1	1	1	1	1	1		95	80
51					-	-	-	-	2	2	0	0		95	95
58					5	5	5	5	15	15	15	15		95	85
149	Equivocal	-	-	-									72		
205	-	-	-	++					-	-	-	++	80		80
212					-	-	-	-	-	-	-	-		100	100
311					1	1	1	1	1	1	1	1		100	90
315					Equivocal	Equivocal	Equivocal	Equivocal	Equivocal	Equivocal	Equivocal	Equivocal		50	25